No-Deal Brexit May Lead To A Fragmented Market
Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.
You may also be interested in...
Draft legislation has been published by the UK’s Intellectual Property Office to ensure that the EU’s supplementary certificate protection manufacturing waiver will continue to function in the case of a no-deal Brexit outcome.
The UK’s participation in Europe’s unified patent court (UPC) hangs in the balance in the event of no deal being reached on the UK’s ‘Brexit’ departure from the European Union (EU) in March 2019, according to guidance issued by the UK government on intellectual-property (IP) issues relating to pharmaceuticals, including patents and supplementary protection certificates (SPCs). But even with no deal, the UK will continue to offer SPCs.
Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.